Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01391143 · ClinicalTrials.gov registry record · Phase 1
Safety Study of MGA271 in Refractory Cancer
A Phase 1 study, sponsored by MacroGenics.
- Completed
- Registry status
- Phase 1
- Development phase
- 179
- Enrollment target
NCT01391143 is a Phase 1 study that has completed, run by MacroGenics. The registered enrollment target is 179 participants.
The verdict
NCT01391143, a Phase 1 study, has completed, sponsored by MacroGenics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 179 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety of MGA271 when given by intravenous (IV) infusion to patients with refractory cancer. The study will also evaluate how long MGA271 stays in the blood and how long it takes for it to leave the body, what is the highest dose that can safely be given, and whether it may have an effect on tumors.
Interventions
- BIOLOGICAL MGA271
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 179 participants |
| Start Date | 2011-07 |
| Est. Completion | 2019-04-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01391143
The ClinicalTrials.gov registry entry for NCT01391143 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 179 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MacroGenics, which has 36 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MGA271 is the first listed.
NCT01391143 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01391143 about?
NCT01391143 is a clinical study titled "Safety Study of MGA271 in Refractory Cancer". The purpose of this study is to evaluate the safety of MGA271 when given by intravenous (IV) infusion to patients with refractory cancer. The study will also evaluate how long MGA271 stays in the blood and how long it takes for it to leave the body, what is the highest dose that can safely be given,...
What is the current status of trial NCT01391143?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 179 participants. The study started on 2011-07. Estimated completion is 2019-04-18.
What interventions are being tested in trial NCT01391143?
The interventions under investigation include: MGA271 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01391143?
This trial is sponsored by MacroGenics, which has 36 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.